DirectBio develops molecular diagnostic assays using natural and AI-engineered CRISPR enzymes
DirectBio develops molecular diagnostic assays using natural and AI-engineered CRISPR enzymes. Its tests aim to be faster, simpler, and more scalable than conventional PCR by requiring fewer reagents and avoiding nucleic-acid extraction, amplification, and reverse transcription. The platform can detect multiple viruses, bacteria, or biomarkers from a single sample.